PureTech HealthPRTC
About: PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Employees: 90
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
24% more capital invested
Capital invested by funds: $1.87M [Q4 2024] → $2.32M (+$449K) [Q1 2025]
20% more funds holding
Funds holding: 5 [Q4 2024] → 6 (+1) [Q1 2025]
0.01% more ownership
Funds ownership: 0.16% [Q4 2024] → 0.16% (+0.01%) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for PRTC.
Financial journalist opinion
